Welcome to the latest issue of Pharma Marketing News. This is the Executive Summary version. You can download the full-text version of the complete newsletter at: https://www.pharma-mkting.com/news/pmnews3_8hsubx.pdf

Vol. 3, No. 8: September 2004 – CONTENTS

Up Front

Feature Article

Policy Analysis

Guest Article

Conference Highlights

Surveys

Conference Calendar

Upfront
Drug Importation Crisis: Terror Politics to the Rescue!

obn The FDA just played the “terrorist trump card” in its battle against the legalization of the reimportation of drugs. Acting U.S. Food and Drug Administration commissioner Lester Crawford suggested that “a source of continuing concern” is that terrorists might tamper with prescription drugs imported from Canada.

Crawford’s remarks may strike some as politically motivated and Brian Roehrkasse, spokesman for the Homeland Security Department responded to Crawford’s remarks by saying “While we must assume that such a threat exists generally, we have no specific information now about any al-Qaida threats to our food or drug supply.”

FDA also claims that drugs from Canada may be unsafe because they may be counterfeit, cheap foreign copies of FDA-approved drugs, expired, contaminated or stored under inappropriate and un-safe conditions. These arguments have some merit and point out we have a lot more to fear from unscrupulous profiteers than from terrorists when it comes to the safety of our drug supplies.

Reimportation is a growing and real concern for the pharmaceutical industry-in 2002, the American people imported about $1.1 Billion worth of drugs from Canada. To add to the industry’s woes, Congress is considering several bills that seek to make drug importation from Canada legal. There is a chance that one of these bills will be passed, if not in this session of Congress, then perhaps the next (see article, “Congress Fiddles While Reimportation Issue Burns”).

Let’s not try to win every policy argument by bringing terrorism into the equation. I think it undermines our vigilance against real terror threats. Remember the moral of Aesop’s fable about the little shepherd boy: There is no believing a liar, even when he speaks the truth.

IMHO,

John MackJohn Mack Signature
John Mack, Publisher and Editor
editor@pharmamarketingnews.com What Do You Think?

There are other arguments against reimportation of drugs including negative impact on R&D, no guarantee that it would be cheaper, etc. Which do you agree with?

Take our Drug Reimportation Survey and tell us what YOU think about this issue!


ADVERTISEMENT
6th Annual Conference on Guidelines for Disseminating Off-Label Information


Article Summaries


FEATURE ARTICLE


The Indian Pharmaceutical Market
Todd Clark

The Indian pharmaceutical market is the world’s fourth largest by volume (8% of global total) and thirteenth largest by value (less than 1% of global total). Although prices are the lowest in the world, 70% of the population does not have access to drug therapy and 2002 per capita consumption was only $3.33. The lack of pharmaceutical patents means that there is an average of 200 brands for every molecule on the market.

This except from the PharmaHandbook™ 2004 Edition covers the following topics:

  • Patent Protection
  • R&D / Clinical Trials
  • Generics
  • Marketing

More…

PDFRead the full text of this article (includes tables; PDF format).

PMN38-01
Issue: Vol. 3, No. 8: September 2004
Word Count: 1629
TOPICS: Strategy/Planning


POLICY ANALYSIS


Congress Fiddles While Reimportation Issue Burns
By John Mack

Several drug re-importation bills are currently being considered in Congress.

Two Senate bills, the Pharmaceutical Market Access and Drug Safety Act of 2004 (S.2328) and the Safe IMPORT Act of 2004 (S.2493), are likely to meet head-to-head in conference committee. While neither may make it out alive in this session of Congress, the issue of re-importation, however, is not likely to go away.

This article offers a useful comparison of the provisions of these bills and illustrates where the lines on the policy debate are being drawn.

Topic headings:

  • The Senate Contenders
  • Comparing Provisions
  • Pharma’s Position
  • Table: Drug Importation Bills in Congress
  • Chart: Pharmaceutical Expenditures as Percent of Total health Expenditure (Canada v.s US)

More…

Order the Full Article Reprint – $9.95

PMN38-02
Issue: Vol. 3, No. 8: September 2004
Word Count: 900
TOPICS: Strategy/Planning


ADVERTISEMENT
Patient Adherence, Compliance and Education


GUEST ARTICLE


How Cheap are Canada’s Drugs Really?
By Aidan Hollis

This article compares pharmaceutical prices paid by governments in the United States and Canada. The comparator prices are those of the Federal Supply Schedule and the Ontario Drug Benefit List, for frequently prescribed brand name medicines.

The price differential between Canadian and US prices is shown to be relatively small, when considering prices charged to governments.

Buyer power exercised by governments is very important in reducing pharmaceutical prices and comparisons between retail prices in the US and government prices in Canada are therefore inappropriate.

More…

PDFRead the full text of this article (includes price table; PDF format).

PMN38-05
Issue: Vol. 3, No. 8: September 2004
Word Count: 1089
TOPICS: Strategy/Planning


CONFERENCE HIGHLIGHT


Becoming Woman Wise: Marketing Healthcare to Women
By Michael Bramwell

“In 92% of households, women are the number one decision makers for most if not all purchases,” said Daria Blackwell, President and CEO, Knowledge Clinic, Inc. She was speaking at the Women’s Health and Wellness Conference held July 15-16 in Iselin, New Jersey. “More than 80% of healthcare purchasing decisions are made by women. Women account for more than half of the population in the United States and it makes absolute sense to market to women where, when, and how they choose,” she continued.

This article summarizes Ms. Blackwell’s presenation and includes eight strategic approaches to women’s health marketing.

Topic headings:

  • Women vs. Men vs. Other Women
  • Audience Segmentation
  • Give Women What They Want

More…

Order the Full Article Reprint – $9.95

PMN38-03
Issue: Vol. 3, No. 8: September 2004
Word Count: 712
TOPICS: Strategy/Planning | Direct-to-Consumer (DTC) Advertising & Marketing


CONFERENCE HIGHLIGHT


Accelerating Your Multicultural Communications
By Michael Bramwell

Multicultural communications can be a powerful addition to the armamentarium of the healthcare marketer. Often the most “successful” campaigns do not reach as wide an audience as possible because of a failure to understand either cultural or linguistic gaps when communicating with ethnic audiences. These people are a fast-growing segment of the population in the United States, and particularly in the area of health, they face huge disparities that call for proactive, aggressive, and ongoing multicultural healthcare commun-ications campaigns.

Why address multicultural communications? “From a business standpoint, it just makes sense. When 30 percent of your audience is ethnic, it no longer becomes a risk to address this audience, but a priority,” said Walter Arenzon, President and Creative Director, Farmacopea, Inc. He was speaking at the Women’s Health and Wellness Conference held in Iselin, New Jersey, July 15-16.

Topic headings:

  • Sex, Drugs, and Salsa Music
  • Effective Multicultural Communications
  • Talk to Ethnic Women

More…

Order the Full Article Reprint – $9.95

PMN38-04
Issue: Vol. 3, No. 8: September 2004
Word Count: 675
TOPICS: Strategy/Planning | Direct-to-Consumer (DTC) Advertising & Marketing